A 19-year-old male who insufflated the designer drug 2C-I developed recurrent seizures, hyperadrenergic state, and serotonin syndrome, leading to prolonged respiratory failure. Comprehensive drug testing confirmed 2C-I. The patient ultimately made a full recovery. This case highlights the potential for severe toxicity from this emerging phenethylamine, with effects including seizures and serotonin syndrome, and underscores the need for awareness among clinicians.
This paper describes the protocol for a feasibility randomized controlled trial that will compare mindfulness-based stress reduction (MBSR) alone, open-label placebo (OLP) alone, and a combined MBSR+OLP intervention for chronic pain. The authors note that MBSR has modest effect sizes and does not engage the endogenous opioid system, while OLP may activate that system. The trial will include an 8-week intervention period with four in-person sessions and a 3-month follow-up. The goal is to assess feasibility and acceptability to inform a future multi-site efficacy trial.